Kupffer cells (KCs), the liver resident macrophages accounting for 80-90% of the total population of fixed tissue macrophages in the body, not only play a key role in host defense via removing particulate materials from the portal circulation, but may also contribute to the pathogenesis of various liver diseases. We have previously demonstrated that KCs play an important role in controlling portal hypertension and hepatocellular injury via releasing thromboxane A 2 (TXA 2 ) in early fibrosis induced by one-week bile duct ligation (BDL). Production of TXA 2 is controlled by cytosolic phospholipase A 2 (cPLA 2 ) that is activated by the interaction of entothelin-1 (ET-1) with its G-protein coupled ET receptor B (ETBR). However, the signaling pathways that contribute to the ET-1-induced activation of cPLA 2 
Introduction
The overproduction of vasoconstrictive endothelin-1 (ET-1) is a hallmark of the portal hypertension associated with disruption of the hepatic microcirculation during the development of fibrosis and cirrhosis (1) (2) (3) (4) . Thromboxane A 2 (TXA 2 ) is a potent cyclooxygenase (COX)-derived vasoconstrictor in the portal circulation and contributes to the overall vascular tone of the hepatic microcirculation (5) (6) (7) . Our lab has shown that Kupffer cell (KC)-derived TXA 2 plays significant roles in the development of portal hypertension and hepatocellular injury in early fibrosis using the one-week bile duct ligation (BDL) model (8) and in mediating the hyperresponsiveness of the portal circulation to the vasoconstrictive effect of ET-1 during endotoxemia (9) . In the same model, we have also shown that the fibrotic stress primes KCs for the release of TXA 2 by inducing the upregulation of cytosolic phopholipase A 2 (cPLA 2 ), COX-2, and thromboxane synthase (TS) (10) , the three key enzymes for its biosynthesis (11) (12) (13) (14) (15) (16) . cPLA 2 is critical for the production of AA-derived eicosanoids due to its high specificity and selectivity for glycerophospholipids containing AA at the sn-2 position (17) (18) (19) . The significance of cPLA 2 in eicosanoid production is further evident as cells and tissues from cPLA 2 -deficient mice fail to produce prostaglandins, leukotrienes, and thromboxanes (20, 21) . It is established that the primary function of cPLA 2  is to mediate agonist-induced release of AA for eicosanoid production (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . The regulation of cPLA 2 activity involves multiple components. However, it is well established that the allosteric effects of intracellular calcium and phosphorylation of serine residues are the primary regulatory mechanisms of cPLA 2 activity (17-19, 22, 28) . The translocation of cPLA 2 from the cytosol to its target membrane is dependent on intracellular [Ca2+] , which binds to the N-terminal C2 domain. This domain is a Ca 2+ and phospholipid binding domain that promotes interaction of cPLA 2 with its target membrane. Although the phosphorylation of Ser505 by p38 mitogen activated protein kinase (p38 MAPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) (29-31), Ser515 by Ca 2+ /Calmodulin protein kinase II (CaMKII) (32) , and Ser727 by MAPK interacting kinase I (Mnk1) (33) have been implicated in the activation of cPLA 2 ; several studies have established that the phosphorylation of Ser505 is critical for maximal activation of cPLA 2 in most cell types in response to agonist stimulation in vivo and in vitro (26, (29) (30) (31) (34) (35) (36) (37) .
Several studies have reported that ET-1 induces the activation of cPLA 2 with the subsequent release of various AA-derived eicosanoids, including TXA 2 , in many cell types by binding to Gq/G11 and Gi coupled ET (A) and ET (B) receptors. The stimulation of Gq has been shown to induce the activation of cPLA 2 and production of eicosanoids via the PLC or PKC mediated activation of ERK1/2. Stimulation of Gi coupled receptors have been reported to lead to the phosphorylation of cPLA 2 and release of AA via the activation of p38 MAPK and ERK1/2, although the intermediates involved in the activation of p38 have not been fully elucidated (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . KCs express ET (B) receptors coupled to Gq/G11 and Gi proteins (48) (49) (50) (51) , and several reports have supported the initial findings by Qui et al of the requirements of both a transient increase in calcium and phosphorylation of ser505, via p38 MAPK or ERK1/2, for the full activation of cPLA 2 and AA release in macrophages (28, 34, 35) .
We have recently reported significant increases in both the phosphorylation of cPLA 2 and production of TXA 2 in KCs of one-week BDL and sham animals in response to ET-1. However the effects were significantly greater in KCs from BDL animals compared to KCs from sham animals (10) . Furthermore, our recent data clearly demonstrated the significance of the ET-1 induced activation of cPLA 2 and subsequent production of TXA 2 in mediating portal hypertension in early stage fibrosis in addition to further establishing the activation of cPLA 2 as the rate limiting step of eicosanoid production. In order to explore possible therapeutic interventions to block the ET-1/TXA 2 production pathway in the treatment of chronic liver diseases such as primary biliary cirrhosis, it is of significant interest to investigate the signaling mechanisms by which KCs release TXA 2 in response to ET-1 under normal physiological conditions and during the hepatic stress associated with BDL induced early stage fibrosis. Therefore, the purposes of the present study were: 1) to delineate Gq/G11 and Gi coupled ETBR induced signaling pathways and intermediates associated with the activation of cPLA 2 and the subsequent production and release of TXA 2 in response to ET-1 in KCs; and 2) to determine whether the hepatic stress of early stage fibrosis alters the signaling pathways through modifications in the expressions or activities of signaling intermediates.
Materials and Methods

Animals
Male Sprague-Dawley rats weighing 250-400 g were housed in a temperature-controlled animal facility with alternating 12:12-h light-dark cycles and fed standard lab chow ad libitum with free access to water. All procedures were performed in accordance with National Institutes of Health guidelines under a protocol approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Charlotte.
BDL-induced portal hypertensive rat liver model
Bile duct ligation (BDL) was performed as previously described (8) . All of the following experiments were performed after one week of surgery. One week of BDL was chosen as the pre-cirrhotic model as previous studies have shown 1) the portal hypertension was well developed at this time point; 2) the injury within the liver was mild but evident; and 3) no overt structural changes in the portal circulation system were observed, although an inflammatory response around the portal triads was obvious.
Kupffer cell isolation and culture
KCs form one week BLD and sham operated Male Sprague-Dawley rats weighing between 250-400 g were isolated as previously described (9, 52) . Cells were plated in 24-well plastic culture dishes (Corning, Corning, NY) at a concentration of 1 × 10 6 cells/well and cultured in 1000 l of RPMI 1640 medium (Sigma Chemical, St. Louis, MO) supplemented with 25 mM HEPES, 20% fetal bovine serum (FBS) and antibiotics (0.05% gentamycin sulfate). The purity of KCs was greater than 95% of adherent cells indicated by immunocytochemistry for ED-1, a cell surface marker for myeloid cells and tissue macrophages, ED-2, which has high specificity for KCs, and Factor 8, a marker for liver endothelial cells. Cells were cultured at 37°C in 5% CO 2 .
Cell treatment
Cultured KCs from one-week BDL and sham animals were randomly assigned to separate experimental treatment groups. In the first group, the culture medium was removed following 24 h in culture. Cells were washed three times with 1× phosphate buffered saline (PBS), and whole cell lysates were Volume 6 Number 6 December 2009 obtained using Radioimmunoprecipitation (RIPA) buffer (50 mM Tris·HCl, 1 mM EDTA, 1% (v/v) Nonidet P-40, 5 mM phenylmethylsulfonyl fluoride, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 50 g/ml aprotinin, 1% (v/v) Triton X-100, and 1 mM Na 2 VO 4 , 4 o C), and lysates were stored at -80 o C prior to analysis (n = 6 for BDL, n = 6 for sham). In the second group, following 24 h in culture, the medium was removed, cells were carefully washed 3 times with PBS, and 1000 l of media containing either vehicle (0.9% saline) or ET-1 (American Peptide, 20 nM final concentration) was added to each well. Prior to and 10 min after the addition of 0.9% saline or ET-1, medium was removed and cells were washed 3 times with PBS. Whole cell lysates were collected using RIPA buffer and stored at -80 o C prior to analysis (n = 4 for BDL, n = 6 for sham). In the final experimental treatment groups, KCs isolated from one week sham and BDL animals were treated with pharmacological inhibitors and reagents or equal concentration of vehicle (v/v) as described in Table 1 . Following 23 h in culture, the medium was removed, cells were carefully washed 3 times with PBS, and 1000 l of media containing either pharmacological reagent or vehicle were added to each well. After one hour of incubation at 37 o C, the medium was removed, and cells were washed 3 times with PBS (in experiments with AACOCF 3 , the cell medium was initially replaced after 21 h in culture, and the incubation time with AACOCF 3 or vehicle was 3 h). Cells were then treated with 1000 l of media containing either ET-1 (20 nM) or 0.9% saline and pharmacological reagent or vehicle (at the same concentrations used in initial treatments) was added to each well. Samples from the media were collected before and 10 min after incubation at 37 o C and stored at -80 o C until measurements of TXB 2, a stable metabolite of TXA 2 as an indicator of TXA 2 productions.
Western blot analysis
Protein quantification of samples was performed using a Micro BCA (bicinchroninic acid) kit (Pierce, Rockford, IL). After quantification, protein samples in Laemmli loading buffer were placed in heating block at 100 o C for seven min and separated by SDS-PAGE on a 12% acrylamide gel, and proteins were electroblotted onto nitrocellulose membranes. Membranes were stained with Ponceau S to confirm equal protein loading and transfer. Membranes were washed three times for five min in TBS with 0.2% Tween 20 (TBS-T), blocked in 5% powdered skim milk (PSM) in TBS-T for 1 h at RT, washed three times for five min in TBS-T, and incubated with primary Ab (1 : 1000 dilution, 5% BSA-TBS-T) overnight at 4 o C. Primary antibodies used for the first experimental treatment group were: anti-ETBR (C-20), anti-Gq (E-17), anti-G11 (D-17), anti-Gi-1/2/3 (N-20), and anti-Actin (I-19) (Santa Cruz Biotechnologies, Santa Cruz, CA). Primary antibodies used for the second experimental treatment group were: anti-phospho-p42/p44 MAPK (ERK1/2) (Thr202/Tyr204), anti-p42/p44 MAPK (ERK1/2), anti-phospho-p38 MAPK (Thr180/Tyr182), and anti-p38 MAPK (Cell signaling Technologies, Danvers, MA). Membranes were washed four times for five min in TBS-T and incubated for 1 h at room temperature with appropriate horseradish peroxidase-conjugated secondary antibody (1 : 2000 dilution 5% PSM-TBS-T) (donkey anti-goat IgG, Santa Cruz Biotechnology; goat anti-rabbit IgG, Cell Signaling Technologies). After 4 washes at 5 min each with TBS-T, membranes were treated with enhanced chemiluminescence reagent (Pierce) for 1 min and exposed to Biomax film (Fisher Scientific, Pittsburgh, PA). Densitometric quantification of Western blot signal intensity of the bands on films was performed using a digital scanner and densitometric analysis program (ImageJ 1.34s, NIH). In the first experimental group, values obtained for protein expressions were normalized with values for the expression of actin. In the second experimental group, in which active (phosphorylated) isoforms of ERK1/2 and p38 were detected, membranes were stripped and re-probed for total ERK1/2 and p38 expression. In calculating the ratios of phosphoprotein to total protein, raw densitiometric values of phospho-protein were divided by the corresponding raw densitometric values for total protein. 2 Enzyme immunoassay kits (Assay Designs, Ann Arbor, MI) were used to determine the concentration of TXB 2 as an indicator of TXA 2 release into the media of cultured KCs. The level of TXB 2 was expressed as fold changes compared to baseline levels. 
Enzyme immunoassay for TXB
Statistical analysis
In vitro productions of TXA 2 with AACOCF 3 or vehicle pretreatment, ratios of phosho-ERK1/2 to ERK1/2 and ratios of phospho-p38 to p38 in ET-1 or vehicle treated KCs of BDL and sham animals were analyzed using a Two-Way ANOVA followed by Student-Newman-Keuls test. Expressions of ETBR, Gq, G11, and Gi in KCs of BDL and sham animals were analyzed by using One-Way ANOVA followed by Student-Newman-Keuls test. In studies using pharmacological reagents, excluding AACOCF 3 , in vitro productions of TXA 2 within sham and BDL groups and between sham and BDL groups were analyzed using a Two-Way ANOVA and Three-way ANOVA, respectively, followed by Student-Newman-Keuls test. A p value < 0.05 was considered significant. All results are presented as mean ± SE.
Results
Essential role of Ca 2+ -dependent cPLA 2 in the release of TXA 2 from ET-1 stimulated KCs of sham and BDL animals To investigate the role of Ca 2+ -dependent cPLA 2 in the production of TXA 2 in response to ET-1 in KCs under normal conditions and in the presence of the hepatic stress associated with early stage fibrosis, we determined the effects of the pharmacological inhibition of cPLA 2 with AACOCF 3 and the chelation of calcium with BAPTA-AM on TXB 2 (a stable metabolite of TXA 2 ) levels in the media of KCs from one-week sham and BDL animals prior to and 10 min after incubation with ET-1 or saline.
As shown in Figure 1A , the basal levels of TXB 2 in media of BDL KCs without ET-1 and AACOCF 3 treatment were significantly greater than the levels in the corresponding sham group. ET-1 treatment elevated TXB 2 levels in both sham and BDL KCs. Such elevation was significantly greater in BDL KCs than those in sham group. The inhibition of cPLA 2 with AACOCF 3 completely abrogated the release of TXA 2 from all groups, clearly demonstrating the essential role of cPLA 2 in the production of TXA 2 in KCs. Figure 1B shows that the chelation of calcium with BAPTA-AM abrogated ET-1-mediated induction of TXA 2 in KCs of sham and BDL animals but had no effect on the basal levels of TXA 2 in KCs without ET-1 treatment.
Altered roles of ERK1/2 and p38 MAPK in the ET-1 induced releases of TXA 2 from KCs of one-week sham and BDL-induced portal hypertensive animals
To delineate the roles of ERK1/2 and p38 MAPK in the ET-1-induced activation of cPLA 2 and releases of TXA 2 from KCs under normal conditions and in the presence of the hepatic stress associated with early stage fibrosis, we investigated the activation of ERK1/2 and p38 MAPK in KCs from one-week sham or BDL animals prior to and 10 min after incubation with ET-1 or saline, and determined the effects of the pharmacological inhibition of ERK1/2 activation with PD98059 and the inhibition of p38 with SB203580 on TXB 2 levels in these groups.
As shown in Figures 2A-2B , treatment with ET-1 induced similar levels of ERK1/2 activation in KCs from both one-week sham and BDL animals. Figure 2C shows that the inhibition of ERK1/2 with PD98059 did not affect the basal levels of TXA 2 in KCs of sham or BDL animals. Interestingly, PD98059 treatment abrogated the ET-1 induction of TXA 2 to basal levels in KCs of sham animals but only slightly without statistically significant difference affecting the ET-1 induction of TXA 2 in KCs of BDL animals.
Figures 3A-3B show that treatment with ET-1 induced markedly p38 MAPK activation (phosphorylation) in KCs from BDL animals and such induction was suppressed in KCs of sham animals. Figure 3C shows that in KCs of sham animals, the inhibition of p38 with SB203580 had no effect on the release of TXA 2 in response to saline treatment or ET-1 treatment. In KCs of BDL animals, SB203580 treatment reduced significantly the ET-1 induction of TXA 2 but did not affect the basal levels of TXB 2 . These data suggest that ERK1/2 and p38 MAPK play an important role in ET-1 induction of TXB 2 in KCs of sham and BDL animals, respectively.
Modified expressions of the ETBR and associated G proteins and corresponding altered Gq and Gi signaling in the ET-1 induced releases of TXA 2 from KCs of one-week sham and BDL animals
To determine whether the fibrotic stimulation of one-week BDL induces modifications of ET-1 signaling at the receptor level, we measured protein levels of the ETBR and associated  subunits of Gq, G11, and Gi, by Western blot analysis. As shown in Figure 4 , the protein expressions of the ETBR and Gi were significantly enhanced in KCs of one-week BDL animals compared to the expressions in sham animals. However, the expressions of Gq and G11 were significantly reduced in KCs from one-week BDL animals compared to that in sham animals.
To investigate whether the altered expressions of the ET (B) receptor and G subunits in KCs following the hepatic stress are associated with modified ET-1 signaling and to determine the relative contributions of Gq/G11 and Gi signaling in the ET-1 induced activation of cPLA 2 and release of TXA 2 in KCs of sham and BDL animals, we determined KCs in response to hepatic stress. KCs were isolated and cultured as described in Figure 1 . After 24 h in culture, whole cell lysates were collected at 0 and 10 min following 20 nM ET-1 or saline treatment. Western blot analysis for phospho-p38 MAPK and total p38 MAPK (A) and densitometric analysis and ratios of p-p38 to total p38 (B) were performed as described in Materials and Methods. *p < 0.05. In separate experiments KCs were pretreated with 10 M SB203580 or vehicle prior to incubation with 20 nM ET-1 or saline. Media were sampled at 0 min and 10 min following ET-1 or saline treatment for the measurement of TXB 2 levels. Values as fold change at 10 min over time 0 are expressed (mean ± SE). *p < 0.05.
the effects of the pharmacological inhibition of Gq with GP2A and the inhibition of Gi with PTX on TXB 2 levels in these groups. As seen in Figure 5A , in KCs of sham animals, the inhibition of Gq signaling with GP2A diminished the ET-1 induction of TXA 2 to the basal levels but had no effect on the basal levels of TXB 2 . Within KCs of BDL animals, GP2A treatment reduced slightly but not significantly the ET-1 induction of TXB 2 levels, and did not affect the basal levels of TXB 2 levels either.
As shown in Figure 5B , within KCs of sham animals, the inhibition of Gi signaling with PTX affected neither the basal levels nor the ET-1 induction of TXB 2 levels. Within KCs of BDL animals, PTX treatment diminished significantly ET-1 induction of TXB 2 levels but did not affect the basal levels of TXB 2 .
Critical roles of PLC and PKC in the ET-1 induced releases of TXA 2 from KCs of one-week sham and BDL animals To investigate the roles of PLC and PKC in the ET-1 induced activation of cPLA 2 and release of TXA 2 from KCs of sham and BDL-induced early stage fibrotic livers, we determined the effects of the pharmacological inhibition of PLC with U73122 and PKC with Calphostin C on TXB 2 levels.
As seen in Figures 6A-6B , U73122 and Calphostin C had similar effects on attenuating the ET-1 induction of TXB 2 in KCs from both sham and BDL animals but had no effect on the basal levels of TXB 2 . These data clearly suggest that PLC and PKC are key signaling intermediates in the ET-1 induced activation of cPLA 2 and production of TXA 2 in KCs in both the absence and presence of hepatic stress induced by one-week BDL animals. B5  B6  S1  S2 S3 S4 S5 S6   ETBR   -49   B1 B2 B3 B4  B5  B6  S1  S2 S3 S4 S5 S6   49   B2 B3 B4  B5  B6  S1 S2 S3 S4 S5 S6 
B1 B2 B3 B4
Discussion
KCs account for 80-90% of total population of tissue macrophages in the body, which not only play an important role in host defense via removing particulate materials from the portal circulation, but may also contribute to the pathogenesis of various liver diseases (53, 54) . We have previously demonstrated that KCs play an important role in controlling portal hypertension and hepatocellular injury via releasing thromboxane A 2 (TXA 2 ) in early fibrosis induced by one-week bile duct ligation (BDL), and that ET-1 plays an important role in stimulating TXA 2 production in KCs via binding to ETBR (10) . In the current study, we have demonstrated that several downstream signaling pathways play an important role in ET-1-mediated induction of TXA 2 in KCs, and that these pathways contribute differently to the ET induction of TXA 2 in KCs from sham or BDL animals ( Figure 7) . The increased production of ET-1 and an increased sensitivity and responsiveness of the portal circulation to ET-1 are associated with the disruption of the hepatic microcirculation in response to hepatic stresses. TXA 2 produced by KCs has been demonstrated to contribute to hepatic injury and increased resistance of the portal venous system associated with the microcirculatory disturbance in response to the hepatic stress during the early stages of fibrosis (8) . In our previous studies, the increased expressions of cPLA 2 , COX-2, and TS coincided with significantly enhanced production of TXA 2 in ET-1 stimulated KCs from one-week BDL-induced portal hypertensive early stage fibrotic animals compared to KCs from sham controls (10) . ET-1 induced the phosphorylation of cPLA 2 at ser505 in KCs from BDL and sham animals; however, the effect was significantly greater in KCs from BDL animals. In other cell types, ET-1 has been demonstrated to activate cPLA 2 and the release of various eicosanoids including TXA 2 , via binding to Gq/G11 and Gi coupled ET (A) and ET (B) receptors, subsequently inducing the activation of ERK1/2 or p38 MAPK through PLC or PKC mediated signaling pathways (38, 39, 41, 42, 44, 45, 47, (55) (56) (57) (58) (59) (60) (61) . Therefore, the purposes of the present study were to delineate the signaling pathways induced via stimulation of Gq/G11 and Gi coupled ETBRs and the relative roles of intermediates in the activation of cPLA 2 and production of TXA 2 in KCs in response to ET-1, and determine whether the hepatic stress of early stage fibrosis alters the signaling pathways through modifications in the expressions or activities of signaling intermediates.
The liberation of free arachidonic acid is the rate limiting step during the biosynthesis of eicosanoids, including prostaglandins and thromboxane A 2 (22) (23) (24) (25) . The primary means by which AA is released from membranes is the agonist induced activation of the calcium dependent group IV  isoform of cPLA 2 , due to its high specificity and selectivity for glycerophospholipids containing AA at the sn-2 position. Although the agonist induced activation of cPLA 2  has been established as the rate limiting step of eicosanoid biosynthesis (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , the deacylation of diacylglycerol (DAG) via DAG lipase also produces AA for the synthesis of eicosianoids. In addition, DAG lipase has been suggested to mediate the release of AA in KCs (56, 62) . Therefore, we first determined whether the productions and releases of TXA 2 in ET-1 stimulated KCs from BDL and sham animals are mediated solely by the activation of calcium dependent cPLA 2 .
The pharmacological inhibition of cPLA 2 with AACOCF 3 , a potent and selective inhibitor of cPLA 2 , fully attenuated the ET-1 induction of TXA 2 in KCs isolated from sham and BDL animals. In addition, the inhibition of cPLA 2 abrogated the basal levels of TXA 2 release in the KCs from BDL animals ( Figure 1A ). In KCs from sham or BDL animals, the chelation of calcium with BAPTA-AM also abrogated the ET-1 induction of TXA 2 ( Figure 1B) . These data clearly indicate the critical role of cPLA 2 in the ET-1 induction of TXA 2 from KCs from both sham and BDL animals. In addition, these data support previous reports of the critical role of calcium in the activation of cPLA 2 in KCs (28) .
Interestingly, the basal and ET-1 induced TXB 2 levels in the media of KCs from BDL animals were significantly greater than the corresponding groups in KCs from sham animals ( Figure 1 ). Several studies have confirmed that the phosphorylation of cPLA 2 at Ser505 via ERK1/2 or p38 MAPK, in addition to a transient increase in [Ca 2+ ]i, is critical for maximal enzymatic activity of cPLA 2 in macrophages. We have previously demonstrated that the basal and ET-1 induced activation of cPLA 2 were significantly higher in KCs from BDL animals compared to KCs from sham animals (10) . These effects may potentially account for the higher basal and ET-1-induced TXB 2 levels in BDL KCs than sham KCs. To gain further insight into the enhanced ET-1 induced phosphorylation of cPLA 2 in KCs from early stage fibrotic livers, we investigated the relative roles of ERK1/2 and p38 MAPK in the activation of cPLA 2 and production of TXA 2 in KCs from sham and BDL animals.
Despite displaying a similar responsiveness to ET-1 (Figures 2A-2B) , the inhibition of ERK1/2 abrogated the ET-1 induction of TXA 2 from KCs of sham rats but only resulted in a modest, yet noticeable, reduction in the production of TXA 2 in ET-1 treated KCs from early stage fibrotic livers ( Figure 2C ). In contrast, p38 MAPK from KC of BDL animals displayed a markedly enhanced responsiveness to ET-1 compared to that seen in sham KCs (Figures 2A-2B) . Indeed, increased expression and activity of p38 MAPK have been reported in KCs from fibrotic livers (41, 61, 63) . Furthermore the inhibition of p38 had no apparent effect on the ET-1 induced release of TXA 2 from KCs of sham rats, but completely abrogated the production of TXA 2 in ET-1 treated KCs from early stage fibrotic livers ( Figure 2C ). These data suggest a critical role of ERK1/2, but not p38, in the ET-1 induced activation of cPLA 2 and production of TXA 2 in KCs under normal conditions. In response to the hepatic stress associated with the early stages of fibrosis, p38 MAPK clearly plays a more prominent, but not exclusive role than ERK1/2 in the activation of cPLA 2 and release of TXA 2 from ET-1 stimulated KCs. As the extent to which ET-1 activated ERK1/2 was statistically the same in KCs from sham and BDL animals, and the inhibition of ERK1/2 tended to decrease the production of TXA 2 in ET-1 treated KCs from BDL animals. Our previous observations of the significantly enhanced phosphorylation of cPLA 2 in response to ET-1 in KCs from BDL animals compared to KCs of sham animals (10) could be an additive effect of the kinase activities of ERK1/2 and p38 MAPK in response to ET-1.
As KCs express Gq/G11 and Gi coupled ETB receptors (48-51), we investigated the contributions of Gq/G11 and Gi signaling in the ET-1 induced activation of cPLA 2 and production of TXA 2 in KCs under normal conditions and in response to the hepatic stress of early stage of fibrosis. In the absence of fibrotic stress, inhibiting Gi signaling with PTX did not significantly attenuate the release of TXA 2 in response to ET-1. However, we can not exclude a minimal contribution from Gi coupled ET (B) R induced signaling, as TXB 2 levels in media of PTX treated KCs in response to ET-1 were statistically the same as vehicle and PTX treated KCs in response to saline. Nevertheless, the activation of cPLA 2 and production of TXA 2 in KCs treated with ET-1 is clearly mediated by signaling induced upon the stimulation of Gq/G11 coupled ETB receptors, as the inhibition of Gq abrogated the ET-1 induced release of TXA 2 ( Figure 5A ).
Increased ETBR mRNA and protein have been reported in the cirrhotic livers of patients (4, 64) and on nonparenchymal cells of CCL 4 induced cirrhotic livers in rats (65) . In response to the hepatic stress of early fibrosis, the activation of cPLA 2 and production of TXA 2 in response to ET-1 in KCs is predominately mediated by Gi coupled ETBR as the inhibition of Gi abrogated the release of TXA 2 in response to stimulation with ET-1. Moreover, in KCs from BDL animals, we observed significantly increased expressions of the ETBR and Gi subunit yet decreased levels of Gq and G11 (Figure 4 ). These changes in protein expressions in response to early fibrotic stimulation correlated with our observations of respective contributions of Gq/G11 and Gi coupled ETBR signaling in the ET-1 induced activation of cPLA 2 and production of TXA 2 . The  subunits of Gi have been reported to lead to the activation of p38 (66) , and previous studies have demonstrated that p38 MAPK induced the phosphorylation of cPLA 2 and releases of AA in response to ET-1 via Gi coupled ETA receptors (47, 61) . Therefore, the increased responsiveness of p38 MAPK to ET-1 observed in KCs from early stage fibrotic livers could be attributed to the increased expression of Gi coupled ETBRs.
Several studies have demonstrated PLC and PKC to be key signaling intermediates in the ET-1 induced activation of cPLA 2 and release of AA and AA-derived eicosanoids. It is established that the function of Gq and G11 proteins is to stimulate PLC, which subsequently leads to the production of DAG and increase in [Ca 2+ ]i, both products are required for the activation of PKC , a prominent activator of MEK1/2 -ERK1/2 signaling. In the present study, PLC and PKC were identified as key components in the signaling pathways in the activation of cPLA 2 and production of TXA 2 in KCs stimulated with ET-1 in the absence of fibrotic stimulation, as the inhibition of either abrogated the release of TXA 2 in response to ET-1 ( Figure 6) . Therefore, our data suggest that in the absence of hepatic stress, the activation of cPLA 2 and production of TXA 2 in KCs in response to ET-1 is through stimulation of Gq/G11 coupled ETBRs and the subsequent activation of PLC. The PLC dependent hydrolyzation of phosphatidylinositoldiphosphate (PIP2) produces inositol trisphosphate (IP3), which induces increased intracellular Ca 2+ , and diacyl glycerol (DAG). The subsequent activation of DAG and calcium dependent PKC , activates MEK1/2 -ERK1/2 signaling with the subsequent phosphorylation of cPLA 2 . The IP3 induced increase in intracellular [Ca 2+ ] in conjunction with the phosphorylation of cPLA 2 , leads to the maximal activation of cPLA 2 and production of TXA 2 . However we can not exclude the possibility of a small contribution by Gi coupled ETBRs to the release of TXA 2 in response to ET-1. As the inhibition of p38 had no effect on the ET-1 induced release of TXA 2 , it is likely that ERK1/2 is activated following stimulation of the Gi coupled ETBRs ( Figure 7A ).
In the present study, PLC and PKC were found to be critical intermediates in the signaling pathways in the activation of cPLA 2 and production of TXA 2 in KCs stimulated with ET-1 in response to the hepatic stress of early stage fibrosis, as the inhibition of either abrogated the release of TXA 2 in response to ET-1 ( Figure 6 ). In addition to Gq/G11, it is well documented the  dimer of Gi proteins stimulate the activation of PLC (57, (67) (68) (69) (70) (71) . PLC activated by the  dimer of Gi proteins has been demonstrated to mediate the activation of cPLA 2 and release of AA in response to ET-1 (57, 71). Gandhi et al reported that the release of PGE 2 from ET-3 stimulated KCs is mediated by PLC. In addition, PTX attenuated the activation of PLC and release of PGE 2 in response to . However, Gq coupled ETBRs appear to play a minor role in the activation of cPLA 2 and production of TXA 2 in KCs stimulated with ET-1 in response to the hepatic stress of early stage fibrosis. As the stimulation of PLC can mediate both allosteric regulatory mechanisms of cPLA 2 activity, specifically the IP3 induced increase in [Ca 2+ ]i and the PKC-MEK activation of ERK1/2, further studies are needed to investigate the regulation of PLC activity by Gq/G11 and the  dimer of Gi coupled ETBRs in KCs during the development of fibrosis.
PKC has been reported to play significant roles in the early stages of fibrosis and development of cirrhosis, and mediating the activation of cPLA 2 and release of AA in response to ET-1 (72) (73) (74) . Mustafa et al. demonstrated that either 4-bromophenacyl bromide, a nonspecific PLA 2 inhibitor, or PTX inhibited the ET-1 induced synthesis of platelet activating factor (PAF) in KCs. In addition, the pretreatment with staurosporine, a PKC inhibitor, attenuated the release of PAF in response to ET-1 (72, 75) . In the CCl 4 model of fibrosis, Jeong et al. demonstrated the increased activity of PKC preceded the morphologic changes of the liver architecture (73) . KCs express the Ca 2+ dependent  and Ca 2+ independent  isoforms of PKC, both of which have been implicated in the activation of cPLA 2 and release of AA (74) . In addition, PKC , which stimulates both p38 MAPK and ERK1/2 signaling, has been demonstrated to be critical for the release of TXA 2 in other cell types (76) .
Collectively, these data clearly demonstrate significant changes in ET-1 signaling intermediates in KCs, including the increased expression of Gi coupled ETBRs, decreased expression of Gq/G11 coupled ETBRs, and the increased responsiveness of p38 to ET-1 during the early stages of fibrosis. Despite decreased Gq/G11 coupled ETBRs, the responsiveness of ERK1/2 to ET-1 remained unchanged. Therefore, the activation of ERK1/2 in conjunction with the enhanced activity of p38 MAPK in response to ET-1 likely attributes to the increased phosphorylation of cPLA 2 and subsequent enhanced production of TXA 2 in KCs. Figure 7 illustrates our working hypothesis on the changes of ET-1 signaling in KCs during the early development of fibrosis. In conjunction with our previous findings, our data demonstrated that the elevated productions of TXA 2 and increased portal resistance during the development of fibrosis is mediated by the enhanced activation of cPLA 2 and increased productions of TXA 2 in response to ET-1, in parallel with upregulations of key enzymes of TXA 2 biosynthesis in KCs. In addition to the enhanced expressions of key enzymes of TXA 2 biosynthesis, we also observed significant modifications in critical signaling intermediates in the ET-1 induced activation of cPLA 2 and production of TXA 2 including increased ETBR expression, altered expressions of associated G proteins, and increased p38 MAPK responsiveness to ET-1, in response to early stage fibrotic stress. Furthermore, these data provide further insight into the mechanisms of the enhanced release of TXA 2 associated with portal hypertension and the increased production of ET-1 and microcirculatory dysfunction during the early stage fibrosis and provide critical information needed for the development of possible therapeutic interventions to block the ET-1/TXA 2 production pathway in the treatment of chronic liver diseases such as primary biliary cirrhosis.
